COO:NASDAQThe Cooper Companies, Inc. Analysis

The Cooper Companies delivered a solid Q1 2026, posting 6.2% revenue growth to $1.02 bn and a 20% jump in EPS to $1.10, while raising guidance despite regional headwinds. The results lifted the forward EPS outlook to $5.02, compressing the forward P/E to ~15 versus a trailing P/E of 37, yet the stock slipped, trading around $74.4, just above the computed support of $72.76 and well below the recent high of $84.62. Technicals show the RSI at 25 (oversold) and a bearish MACD histogram, but volume is increasing, indicating some buying interest.
Valuation metrics flag a substantial disconnect: a DCF‑derived fair value of $20.5 and a price‑to‑earnings gap versus the industry average (37 vs 25) suggest the shares are overvalued. The beta (~0.84) and 30‑day volatility (~24%) point to moderate market risk, while the healthcare‑device sector carries medium regulatory exposure. Given the strong earnings momentum but inflated price, the near‑term outlook favors a cautious stance, the medium term leans toward holding, and the long term raises concerns about price correction.